Transgene Biotek Ltd has closed its trading window for dealing in securities effective October 1, 2026. This restriction applies to all Directors, Key Managerial Personnel (KMPs), Designated Employees, and Connected Persons as defined under the SEBI (Prohibition of Insider Trading) Regulations, 2015.

The trading window will remain closed until 48 hours after the declaration of the company's limited reviewed financial results for the second quarter ended September 30, 2026. This measure ensures compliance with insider trading norms during the sensitive period preceding the release of quarterly earnings.

Board meeting schedule

The company stated that the specific date of the Board Meeting for considering the un-audited financial results for the quarter ended September 30, 2026, will be intimated in due course. The filing was addressed to the Department of Corporate Services at BSE Limited on September 22, 2026.

Regulatory compliance details

The closure is mandated under the SEBI (Prohibition of Insider Trading) Regulations, 2015, read with subsequent amendments regarding trading restriction periods. The Managing Director, Dr K Koteswara Rao, signed the intimation letter to the stock exchange.

Transgene and ProBioGen have broadened the scope of their existing collaboration through an additional license agreement for ProBioGen's AGE1.CR.pIX suspension cell line, aimed at enhancing Transgene's manufacturing capabilities.

Expanding an established manufacturing partnership

The additional license agreement centres on ProBioGen's AGE1.CR.pIX suspension cell line platform, which is designed to enable highly efficient manufacturing processes for vaccine production. The platform supports reliable, cost-effective production and increased productivity. The continued partnership underscores a shared commitment to advancing vaccine innovations through manufacturing scalability and optimisation support.

About the AGE1.CR.pIX platform

ProBioGen's AGE1.CR.pIX cell line is a stable proliferating avian cell line derived from primary cells of a duck embryo, developed as an alternative to the use of chicken eggs for large-scale vaccine production. Key characteristics of the platform include:

• Available as both a suspension and adherent cell line
• Optimised for viral vaccine production and stability
• Grows in a commercially available, chemically defined medium without animal components
• Qualified as a GMP master cell bank, ensuring every batch begins from the same fully characterised starting material
• Supports reproducible, scalable, and transferable manufacturing processes

Leadership perspectives on the agreement

Dr. Alessandro Riva, Chairman and Chief Executive Officer of Transgene, said the additional license reflects confidence in the technology to prepare for future clinical needs at scale. Dr. Volker Sandig, Chief Scientific Officer at ProBioGen, noted that a continuous cell line qualified as a GMP master cell bank, grown in chemically defined and animal-component-free medium, means every batch begins from the same fully characterised starting material, providing a foundation that is reproducible, scalable, and straightforward to transfer.

About the companies

Transgene is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Its clinical-stage portfolio includes viral vector-based immunotherapeutics, with TG4050 as its lead asset — an individualised therapeutic vaccine based on the myvac platform with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. TG4070, a second individualised vaccine candidate from the myvac platform, is in Phase 1 clinical development in combination with nivolumab in adjuvant non-small lung cancer. The company also has BT-001, an oncolytic virus based on the Invir.IO viral backbone, in clinical development.

ProBioGen is a Berlin-based contract development and manufacturing organisation specialising in biopharmaceuticals, viral vectors, and vaccines. Operating for over 30 years, ProBioGen runs three manufacturing lines in Berlin, where 300 employees contribute to advancing next-generation therapies and global biotech innovation.